PROspective ACcrual To Investigate reprOductive Cancers in womeN
| Registry | NCT06527157, acronym PROACTION: |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Enrollment | 4500 (Estimated) |
| Sponsor | PinkDx, Inc. (Industry) |
| Conditions | Uterine Cancer |
| Dates | start 2024-07-30, primary completion 2026-10-30 (estimated), completion 2031-11-15 (estimated), first posted 2024-07-30, last updated 2026-08-17 |
| Locations | 16 sites in United States |
Related Papers Related Patents Related Grants Related Experts
All trials for Uterine Cancer
The goal of this study is to create a non-invasive diagnostic test to rule out gynecological cancer in females aged 45 and older with abnormal uterine or postmenopausal bleeding.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Benign | sample collection from females with benign causes of AUB/PMB | ||
| Malignant | sample collection from females with malignant causes of AUB/PMB |
Sex: Female, ages: 45 Years to 100 Years
Inclusion Criteria: 1. Evidence of a personally signed and dated informed consent form indicating that the subject has been informed of all pertinent aspects of the study. 2. Willing and able to comply with scheduled visits, study plan, and other procedures. 3. Expected to be available for the duration of the study and can be contacted by telephone during study participation. 4. Females aged 45 and older (with roughly 80% of enrolled subjects over the age of 50). 5. Presence of uterus. 6. AUB or PMB being worked up to diagnose the cause of the bleeding Exclusion Criteria: 1. Investigator site staff members directly involved in the conduct of the study and their family members or subjects who are PinkDx, Inc. employees or their family members. 2. Other medical or psychiatric conditions that would increase the risk of study participation in the judgement of the Investigator. 3. Women who have had a hysterectomy. 4. Women with a known history of endometrial cancer or uterine sarcoma. 5. Women who have received prior treatment for endometrial cancer. 6. Inability or unwillingness to sign informed consent. 7. Clinical suspicion of pregnancy. 8. Women who have used a tampon within 7 days of sample collection.
| Facility | City | Country | Status |
|---|---|---|---|
| University of Alabama, Birmingham | Birmingham, Alabama | United States | Recruiting |
| Sutter Health | San Carlos, California | United States | Recruiting |
| Advent Health Orlando | Orlando, Florida | United States | Recruiting |
| Ob-Gyne Associates of Lake Forest, Ltd | Lake Forest, Illinois | United States | Active not recruiting |
| Indiana University, Eskenazi Health | Indianapolis, Indiana | United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota | United States | Active not recruiting |
| Washington University School of Medicine | St Louis, Missouri | United States | Recruiting |
| Columbia University | New York, New York | United States | Recruiting |
| Summa Health | Akron, Ohio | United States | Recruiting |
| The Ohio State University | Columbus, Ohio | United States | Recruiting |
| Avera Research Institute | Sioux Falls, South Dakota | United States | Active not recruiting |
| University of Tennessee Health Science Center | Memphis, Tennessee | United States | Recruiting |
| Meharry Medical College | Nashville, Tennessee | United States | Recruiting |
| Baylor College of Medicine/Texas Children's Hospital | Houston, Texas | United States | Recruiting |
| Houston Methodist | Houston, Texas | United States | Recruiting |
| University of Texas Health Science Center at San Antonio | San Antonio, Texas | United States | Recruiting |